Skip to content

Registration for 2024 Annual Ataxia Conference is NOW OPEN! Early-bird discount available for a limited time.  LEARN MORE!

SCA17 Treatment Pipeline

Tracking progress of the development of SCA17 therapies.

Pipeline for SCA17

This is a visual tool created to show the progress of SCA17 therapies that are currently being developed. Along the right side of the diagram, treatments are grouped by their mechanism, or how the drug works. The top of the diagram shows the stage of research where the drug is in development. Phases 1 through 3 involve clinical trials with human participants. Visit our PrepRARE: Clinical Trial Readiness Education page to learn more about each phase.

Once clinical trials provide enough evidence to prove that the drug is safe and effective, the sponsor of the drug can apply for regulatory approval of the drug. After regulatory approval, the drug can become available to individuals through their healthcare provider.

The agency responsible for reviewing and approving new treatments varies depending on where you are in the world. Some regulatory agencies include:

You can click the links above to learn more about each regulatory agency. This includes information about how they approve new medications.

Please note that a drug’s status is subject to change. Please visit clinicaltrials.gov for the most current information available for specific therapies. Detailed information is available for some of the drugs listed.

To learn more about participating in research visit our PrepRARE Clinical Trial Readiness Education page.

Print Friendly, PDF & Email
Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.